<DOC>
	<DOCNO>NCT00096122</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose tipifarnib give idarubicin cytarabine see well work treat patient newly diagnose myelodysplastic syndrome acute myeloid leukemia . Drugs use chemotherapy , idarubicin cytarabine , work different way stop cancer cell divide stop grow die . Tipifarnib ( Zarnestra ) may stop growth cancer cell block enzymes necessary growth . Giving idarubicin cytarabine tipifarnib may kill cancer cell .</brief_summary>
	<brief_title>Idarubicin , Cytarabine , Tipifarnib Treating Patients With Newly Diagnosed Myelodysplastic Syndromes Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine tolerability combination R115777 ( Zarnestra™ ) Idarubicin plus cytarabine defining DLT MTD . ( Phase I ) II . To determine efficacy combination Idarubicin , cytarabine ZARNESTRA patient high-risk MDS AML . ( Phase II ) OUTLINE : This dose-escalation study tipifarnib . Patients stratify accord age ( &lt; 50 versus ≥ 50 ) , patient ≥ 50 year age , cytogenetics ( diploid versus unfavorable ) . INDUCTION THERAPY : PHASE I : Patients receive cytarabine IV continuously day 1-3 ( 1-4 ) , idarubicin intravenous ( IV ) 1 hour day 1-3 , oral tipifarnib twice daily day 1-21 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PHASE II : Patients receive cytarabine , idarubicin , tipifarnib phase I MTD . Patients phase respond induction therapy proceed consolidation maintenance therapy . CONSOLIDATION MAINTENANCE THERAPY : Patients receive consolidation therapy comprise cytarabine IV continuously day 1-3 , idarubicin IV 1 hour day 1-2 , tipifarnib twice daily day 1-14 . Treatment repeat every 4-6 week 5 course absence unacceptable toxicity . Patients begin maintenance therapy comprise oral tipifarnib twice daily day 1-21 . Treatment repeat every 4-6 week 6 course absence unacceptable toxicity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Diagnosis 1 ) AML ( WHO classification definition &gt; 20 % blast ) , 2 ) high risk MDS ( define presence &gt; 10 % blast ) Patients must chemonaïve , i.e . receive prior chemotherapy ( except hydrea ) AML MDS ; could receive transfusion , hematopoietic growth factor vitamins ; temporary measure pheresis hydrea ( 0.5 5g daily 3 day ) allow ECOG PS 01 screen Creatinine = &lt; 2 mg/dl Total bilirubin = &lt; 2 mg/dL , unless increase due hemolysis Transaminases ( SGPT ) = &lt; 2.5 x ULN Ability take oral medication Ability understand provide sign informed consent Subjects APL Presence active systemic infection Any coexist medical condition judgment treat physician likely interfere study procedure result Nursing woman , woman childbearing potential positive urine pregnancy test , woman childbearing potential willing maintain adequate contraception ( birth control pill , IUD , diaphragm , abstinence , condom partner ) entire course study Known allergy imidazole drug ( clotrimazole , ketoconazole , miconazole , econazole , fenticonazole , isoconazole , sulconazole , tioconazole , terconazole )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>